MedPath

Viracta Therapeutics

Viracta Therapeutics logo
🇺🇸United States
Ownership
Public
Established
2007-01-01
Employees
40
Market Cap
$8.7M
Website
http://www.viracta.com
Introduction

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Phase 1
Recruiting
Conditions
Advanced Cancer
Interventions
First Posted Date
2024-03-08
Last Posted Date
2025-01-08
Lead Sponsor
Viracta Therapeutics, Inc.
Target Recruit Count
14
Registration Number
NCT06302140
Locations
🇪🇸

START Madrid - CIOCC - Hospital Universitario HM Sanchinarro, Madrid, Spain

Nanatinostat Plus Valganciclovir in Patients With Advanced EBV+ Solid Tumors, and in Combination With Pembrolizumab in EBV+ RM-NPC

Phase 1
Active, not recruiting
Conditions
Nasopharyngeal Carcinoma
EBV-Related Gastric Carcinoma
EBV-Related Leiomyosarcoma
EBV Related Carcinoma
EBV-Related Sarcoma
Interventions
First Posted Date
2021-12-22
Last Posted Date
2025-01-08
Lead Sponsor
Viracta Therapeutics, Inc.
Target Recruit Count
26
Registration Number
NCT05166577
Locations
🇺🇸

Stanford Cancer Center, Stanford, California, United States

🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 10 locations

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

Phase 2
Active, not recruiting
Conditions
EBV Related Non-Hodgkin's Lymphoma
EBV-Positive DLBCL, NOS
EBV Related PTCL, NOS
Epstein-Barr Virus Associated Lymphoproliferative Disorder
EBV-Related PTLD
EBV Associated Lymphoma
Interventions
First Posted Date
2021-08-18
Last Posted Date
2025-01-08
Lead Sponsor
Viracta Therapeutics, Inc.
Target Recruit Count
140
Registration Number
NCT05011058
Locations
🇺🇸

The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

David Geffen School of Medicine - UCLA, Los Angeles, California, United States

and more 59 locations

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

Phase 1
Completed
Conditions
Epstein-Barr Virus Associated Lymphoma
Lymphoproliferative Disorders
Interventions
Drug: VRx-3996
Drug: Valganciclovir
First Posted Date
2018-01-12
Last Posted Date
2024-03-05
Lead Sponsor
Viracta Therapeutics, Inc.
Target Recruit Count
64
Registration Number
NCT03397706
Locations
🇺🇸

Georgia Cancer Center at Augusta University, Augusta, Georgia, United States

🇺🇸

Winship Cancer Institute, Emory University, Atlanta, Georgia, United States

🇺🇸

University of California, Los Angeles, Los Angeles, California, United States

and more 25 locations

ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

Phase 2
Completed
Conditions
HIV Infections
First Posted Date
2001-08-31
Last Posted Date
2005-06-24
Lead Sponsor
ViRx
Registration Number
NCT00004582
Locations
🇺🇸

ViRx Inc, San Francisco, California, United States

© Copyright 2025. All Rights Reserved by MedPath